Evidence map›Paper›PMID 36224187›Full record

ReviewNature communications2022

Key considerations to reduce or address respondent burden in patient-reported outcome (PRO) data collection.

Olalekan Lee Aiyegbusi, Jessica Roydhouse, Samantha Cruz Rivera, Paul Kamudoni, Peter Schache, Roger Wilson, Richard Stephens, Melanie Calvert

Open access · goldAbstract readReview
In one paragraph

Review in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 1 pooled it
38.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

98 citing papers in PubMed, 1 synthesis or guideline pooled it, 157 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Patient adherence and response time in electronic patient-reported outcomes: insights from three longitudinal clinical trials.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2024
    Trial
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. AI-based augmentation of oncology clinical trials.Nature reviews. Clinical oncology · 2026
    Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

38 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Olalekan Lee AiyegbusiCentre for Patient Reported Outcomes Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK. O.L.Aiyegbusi@bham.ac.uk.ORCID 0000-0001-9122-8251
Jessica RoydhouseMenzies Institute for Medical Research, University of Tasmania, Hobart, TAS, Australia.ORCID 0000-0002-8025-5841
Samantha Cruz RiveraCentre for Patient Reported Outcomes Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Paul KamudoniEMD Serono Inc, Healthcare Business of Merck KGaA, Darmstadt, Germany.
Peter SchacheLAIFE Reply GmbH, Frankfurt, Germany.
Roger WilsonPatient partner, Centre for Patient Reported Outcomes Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Richard StephensPatient partner, Centre for Patient Reported Outcomes Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.
Melanie CalvertCentre for Patient Reported Outcomes Research, Institute of Applied Health Research, University of Birmingham, Birmingham, UK.ORCID 0000-0002-1856-837X
University of Birmingham · GBCentre for Innovation in Regulatory Science · GBMerck (Germany) · DENational Institute for Health Research · GBUniversity Hospitals Birmingham NHS Foundation Trust · GBUniversity of Tasmania · AU

Funding

Department of Health
6 · The paper itself

Abstract

Patient-reported outcomes (PROs) are used in clinical trials to provide evidence of the benefits and risks of interventions from a patient perspective and to inform regulatory decisions and health policy. The collection of PROs in routine practice can facilitate monitoring of patient symptoms; identification of unmet needs; prioritisation and/or tailoring of treatment to the needs of individual patients and inform value-based healthcare initiatives. However, respondent burden needs to be carefully considered and addressed to avoid high rates of missing data and poor reporting of PRO results, which may lead to poor quality data for regulatory decision making and/or clinical care.

Indexed as

Health PolicyPatient Reported Outcome MeasuresData CollectionDelivery of Health CareHumans

Identifiers

PMID36224187
PMCPMC9556436
OpenAlexW4304731581

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.